ScholarIQanswers from OpenAlex & ORCID
Gordon T. McInnes
ResearcherPublications, citations & collaboration network
Gordon T. McInnes is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Gordon T. McInnes have?
ScholarIQindexed works
Gordon T. McInnes has 192 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Gordon T. McInnes have?
ScholarIQcitation count
Gordon T. McInnes has 19,718 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Gordon T. McInnes?
ScholarIQh-index
Gordon T. McInnes has an h-index of 47 in OpenAlex.
What is the i10-index of Gordon T. McInnes?
ScholarIQi10-index
Gordon T. McInnes has an i10-index of 93 in OpenAlex.
What is the OpenAlex record for Gordon T. McInnes?
ScholarIQopenalex
The OpenAlex for Gordon T. McInnes is on the source record.
What are the most-cited papers on Gordon T. McInnes?
ScholarIQmost cited works
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter Sever, Björn Dahlöf, Neil R Poulter, Hans Wedel, Gareth Beevers, Mark J. Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin OʼBrien, Jan Östergren
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Björn Dahlöf, Peter Sever, Neil R Poulter, Hans Wedel, DG Beevers, Mark J. Caulfield, Rory Collins, Sverre E. Kjeldsen, Arni Kristinsson, Gordon T. McInnes, Jesper Mehlsen, Markku S. Nieminen, Eoin OʼBrien, Jan Östergren
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
Bryan Williams, Thomas M. MacDonald, S. V. Morant, David J Webb, Peter Sever, Gordon T. McInnes, Ian Ford, J. CRUICKSHANK, Mark J. Caulfield, Jackie Salsbury, Isla S. Mackenzie, Sandosh Padmanabhan, Morris J. Brown
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary
Bryan Williams, Neil R Poulter, Morris J. Brown, Mark R. Davis, Gordon T. McInnes, John F. Potter, Peter Sever, Simon Thom
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Bryan Williams, Thomas M. MacDonald, S. V. Morant, David J Webb, Peter Sever, Gordon T. McInnes, Ian Ford, J.K. Cruickshank, Mark J. Caulfield, Sandosh Padmanabhan, Isla S. Mackenzie, Jackie Salsbury, Morris J. Brown, Karthik Balakrishnan, Timothy J. Burton, Jeremy W. Cannon, David Collier, C Coughlan, Richard D’Souza, Enamuna Enobakhare, Elizabeth Findlay, Caroline Gardiner-Hill, Pankaj Gupta, Joanna Helmy, C Helmy, Laura Hobbs, Richard Hobbs, Sally G. Hood, Ray K. Iles, Sharon Kean, See Kwok, P Lacy, I. MacIntyre, Judith Mackay, Nirmala D. Markandu, Una Martin, Linsay McCallum, Gerry P McCann, Andrew W. McGinnis, Vanessa Melville, S. Muir, KS Myint, Salik Nazir, J. Palmer, Richard Papworth, Krzysztof Rutkowski, Manjari Saxena, A. Schumann, Handrean Soran, A Stanley, Simon Thom, David J. Webb, C.W. White, Robert Wilson, Zák A